Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

PHASE4CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

February 21, 2020

Study Completion Date

February 21, 2020

Conditions
Anal Chlamydia Infection
Interventions
DRUG

Azithromycin

Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.

DRUG

Doxycycline

Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.

OTHER

Placebo

Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.

Trial Locations (2)

02115

Fenway Health - The Fenway Institute, Boston

98104-2499

University of Washington - Harborview Medical Center - Center for AIDS and STD, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03608774 - Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM | Biotech Hunter | Biotech Hunter